放射诊疗全景:临床与临床前开发综述
该综述分析了截至2024年12月的活跃临床试验及近期临床前文献,评估放射诊疗的临床与临床前发展格局。靶向生长抑素受体和前列腺特异性膜抗原的药物仍占主导,成纤维细胞活化蛋白、整合素和胃泌素释放肽受体等新靶点正在兴起。下一代治疗性核素和同位素配对等创新有望克服生产、监管和培训障碍。
要点
- 靶向生长抑素受体和前列腺特异性膜抗原的药物仍主导放射诊疗领域。
- 成纤维细胞活化蛋白、整合素和胃泌素释放肽受体等新靶点在临床和临床前开发中兴起。
- β发射体铽-161及α发射体锕-225和铅-212等下一代治疗核素正在研究中。
核心结论
- 放射诊疗通过精准性和适应性改变了癌症治疗,但核素生产、监管框架和人员培训方面的挑战阻碍了更广泛的应用。
- 同位素配对、下一代核素和放射杂交系统在临床前和临床环境中的进展有望克服这些障碍。
- 学术界、产业界和监管机构之间的合作对于加速创新和优化临床结局至关重要。
研究设计与样本
- 综述分析了截至2024年12月来自ClinicalTrials.gov和TheranosticTrials.org的活跃临床试验,并回顾近期文献评估临床前发展。
主要发现
- 靶向生长抑素受体和前列腺特异性膜抗原的药物仍占主导,但成纤维细胞活化蛋白、整合素和胃泌素释放肽受体等新靶点在临床和临床前开发中兴起。
- 小分子和肽仍是最常见的放射性核素载体,基于抗体的载体包括双特异性抗体、免疫球蛋白衍生抗原结合片段和抗体模拟蛋白因特异性和适应性而增加。
- 放射性配体设计创新推动从激动剂向拮抗剂转变,并开发出药代动力学和肿瘤靶向性增强的修饰肽。
- β发射体铽-161及α发射体锕-225和铅-212等下一代治疗核素正在研究,以补充或替代镥-177,满足提高疗效和降低毒性的需求。
- 配对同位素放射性核素因能优化成像和治疗剂量测定而日益流行,放射杂交系统代表在单分子内螯合化学不同核素对的新方法。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Radiotheranostics combines diagnostic imaging with targeted radionuclide therapy, representing a transformative approach in precision oncology. Landmark approvals of Lutathera® and Pluvicto® have catalyzed significant advancements in this field, driving research into novel radionuclides, targeting strategies, and clinical applications. This review evaluates the evolving clinical and preclinical landscape of radiotheranostics, highlighting advancements, emerging trends, and persistent challenges in radionuclide therapy. METHODS: A comprehensive analysis was performed, encompassing active clinical trials as of December 2024, sourced from ClinicalTrials.gov and TheranosticTrials.org. Preclinical developments were evaluated through a review of recent literature, focusing on innovations in radionuclide production, targeting molecules, and radiochemistry. RESULTS: In reviewing the clinical landscape, agents targeting somatostatin receptors (SSTR) and prostate-specific membrane antigen (PSMA) still dominate the field, but new targets such as fibroblast activation protein (FAP), integrins, and gastrin-releasing peptide receptors (GRPR) are gaining traction in both clinical and preclinical development. While small molecules and peptides remain the most common radionuclide carriers, antibody-based carriers including bispecific antibodies, immunoglobin-derived antigen-binding fragments, and antibody-mimetic proteins are on the rise due to their specificity and adaptability. Innovations in radioligand design are driving a shift from agonists to antagonists, accompanied by the development of modified peptides with enhanced pharmacokinetics and tumor-targeting properties. Next-generation therapeutic radionuclides, such as the beta-emitter terbium-161 and alpha-emitters actinium-225 and lead-212, are under investigation to complement or replace lutetium-177, addressing the need for improved efficacy and reduced toxicity. Paired isotopic radionuclides are gaining popularity for their ability to optimize imaging and therapeutic dosimetry as they offer near-identical specificity, biodistribution, and metabolism. Additionally, radiohybrid systems represent an innovative approach to chelating chemically distinct radionuclide pairs within a single molecule, further enhancing flexibility in radiotheranostic design. CONCLUSION: Radiotheranostics has transformed cancer care through its precision and adaptability, but challenges in radionuclide production, regulatory frameworks, and workforce training hinder broader adoption. Advances in isotopic pairing, next-generation radionuclides, and radiohybrid systems in preclinical and clinical settings hold promise to overcome these barriers. Collaborative efforts among academia, industry, and regulatory bodies are critical to accelerating innovation and optimizing clinical outcomes.
引用
- Tran HH, Yamaguchi A, Manning HC, et al. Radiotheranostic landscape: A review of clinical and preclinical development. Eur J Nucl Med Mol Imaging. 2025. PMID: 39891713. doi:10.1007/s00259-025-07103-7
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。